The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross‐sectional study
Alimentary Pharmacology & Therapeutics · 2023
DOI: 10.1111/apt.17502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2023. Verfasst von Dipesh H Vasant und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neurogastroenterology Unit, Gastroenterology Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Fecal Incontinence, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Inkontinenz
Abstract (Originalsprache)
Background
Despite advances in ulcerative colitis (UC) therapies, a relatively undefined proportion of patients experience faecal incontinence (FI) in the absence of active inflammation. For this group, there remains a significant unmet need with a limited evidence base.
Aims
We aimed to estimate the prevalence and impact of FI in UC.
Methods
In a prospective cross‐sectional study, patients with UC completed a series of validated questionnaires, including Rome IV FI criteria, an inflammatory bowel disease (IBD)‐specific FI questionnaire (ICIQ‐IBD), Hospital Anxiety and Depression Scale and IBD‐Control. UC remission was defined as faecal calprotectin (FCP) ≤250 μg/g, or IBD‐control 8 score ≥13 and IBD‐Control‐VAS ≥ 85.
Results
Of 255 patients with UC, overall, 20.4% fulfilled Rome IV criteria for FI. Rome IV FI prevalence did not differ between active and quiescent UC regardless of whether disease activity was defined by IBD‐Control scores ± FCP ( p = 0.25), or objectively with FCP thresholds of 250 μg/g ( p = 0.86) and 100 μg/g ( p = 0.95). Most patients (75.2%) reported FI when in ‘remission’ and during ‘relapse’ (90.6%) according to ICIQ‐IBD. Those who reported FI according to both ICIQ‐IBD and Rome IV definitions had higher anxiety, depression and worse quality‐of‐life (QoL) scores ( p < 0.05). In those with Rome IV FI, there was a strong correlation between FI symptom severity and impaired QoL ( r = 0.809, p < 0.001).
Conclusions
The prevalence of FI in UC is high, even in remission, and associated with significant psychological distress, symptom burden and impaired QoL. These findings highlight the urgent need for further research and development of evidence‐based treatments for FI in UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neurogastroenterology Unit, Gastroenterology Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
- Division of Diabetes, Endocrinology and Gastroenterology, University of Manchester, Manchester, UK.
- Northern Care Alliance NHS Foundation Trust, Greater Manchester, UK.
- Manchester Academic Health Science Centre, Research and Innovation, Manchester University NHS Foundation Trust, Manchester, UK.
- Centre for Biostatistics, Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK.
ORCID-Profile: Dipesh H Vasant, Gaurav B Nigam, Shaheen Hamdy, Jimmy K Limdi
Zitieren
APA
Vasant, D. H., Nigam, G. B., Bate, S., Hamdy, S., & Limdi, J. K. (2023). The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross‐sectional study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17502
Vancouver
Vasant DH, Nigam GB, Bate S, Hamdy S, Limdi JK. The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross‐sectional study. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17502
BibTeX
@article{Vasant2023,
author = {Vasant, Dipesh H and Nigam, Gaurav B and Bate, Sebastian and Hamdy, Shaheen and Limdi, Jimmy K},
title = {The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross‐sectional study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1111/apt.17502}
}
EUVIMED